On May 28, Innovent Biologics fell 3.17% in regular trading, trading at HKD 76.45/share, with trading volume of HKD 650 million.

On the news front, the broader biotechnology sector experienced significant systematic selling pressure, with AKESO down 3.99%, BeiGene down 3.54%, Remegen down 4.25%, and 3SBio down 6.65%, collectively dragging down sector sentiment.

Additionally, market controversy intensified over the company's recent disclosure of purchasing and subscribing to JP Morgan and UBS investment notes totaling USD 690 million. The zero-coupon redeemable notes, maturing between 2027 and 2028 with embedded yields of 4.05%–4.65%, drew criticism from investors who argued the substantial funds should have been allocated toward share buybacks for market capitalization management rather than financial products. This dispute, combined with lingering negative sentiment from the CEO's mid-May share reduction, continued to suppress buying interest in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)